CU23007A1 - Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos - Google Patents

Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos

Info

Publication number
CU23007A1
CU23007A1 CU2001008420010084A CU20010084A CU23007A1 CU 23007 A1 CU23007 A1 CU 23007A1 CU 2001008420010084 A CU2001008420010084 A CU 2001008420010084A CU 20010084 A CU20010084 A CU 20010084A CU 23007 A1 CU23007 A1 CU 23007A1
Authority
CU
Cuba
Prior art keywords
antibody
vaccines
gangliosides
present
tumors
Prior art date
Application number
CU2001008420010084A
Other languages
English (en)
Inventor
Requena Alejandro Lopez Requena Alejandro Lopez
De Acosta Del Rio Cristina Maria Mateo De Ac Mateo
Del Calvo Adriana Maria Rojas Del Calvo Adri Rojas
Navarro Lourdes Tatiana Roque Navarro Lourde Roque
Rodriguez Yildian Diaz Rodriguez Yildian Diaz
Valladares Josefa Lombardero Valladares Lombardero
Molina Luis Enrique Fernandez Molina Lui Fernandez
Gonzalez Alexis Perez Gonzalez Alexis Perez
Perez Adriana Carr Perez Adriana Carr
Lopez Ana Maria Vazquez Lopez Ana Maria Vazquez
Fernandez Angel Mauro Alfonso Fernandez An Alfonso
Rodriguez Rolando Perez Rodriguez Rolando Perez
Original Assignee
Ct De Inmunologia Molecular Ct De Inmunologia Mole
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Inmunologia Molecular Ct De Inmunologia Mole filed Critical Ct De Inmunologia Molecular Ct De Inmunologia Mole
Priority to CU2001008420010084A priority Critical patent/CU23007A1/es
Priority to MYPI20021228A priority patent/MY137078A/en
Priority to ARP020101263A priority patent/AR033122A1/es
Priority to UY27243A priority patent/UY27243A1/es
Priority to MYPI20081190A priority patent/MY145703A/en
Priority to ARP020101264A priority patent/AR033123A1/es
Priority to MYPI20021239A priority patent/MY157372A/en
Priority to UY27242A priority patent/UY27242A1/es
Priority to EP02759751A priority patent/EP1384726B1/en
Priority to AU2002308348A priority patent/AU2002308348B2/en
Priority to CNB028086309A priority patent/CN100349920C/zh
Priority to CZ2003-2668A priority patent/CZ304424B6/cs
Priority to PT02759752T priority patent/PT1411064E/pt
Priority to PT02759751T priority patent/PT1384726E/pt
Priority to DK02759752T priority patent/DK1411064T3/da
Priority to IL15824602A priority patent/IL158246A0/xx
Priority to BRPI0208676A priority patent/BR0208676B1/pt
Priority to AU2002308347A priority patent/AU2002308347B2/en
Priority to EA200301097A priority patent/EA006936B1/ru
Priority to CNB028084330A priority patent/CN1319991C/zh
Priority to SK1216-2003A priority patent/SK287783B6/sk
Priority to JP2002580025A priority patent/JP4366080B2/ja
Priority to MXPA03008739A priority patent/MXPA03008739A/es
Priority to HU0401355A priority patent/HU228106B1/hu
Priority to ES02759752T priority patent/ES2296986T3/es
Priority to EA200301098A priority patent/EA006310B1/ru
Priority to CN2007101021039A priority patent/CN101054417B/zh
Priority to DE60223547T priority patent/DE60223547T2/de
Priority to AT02759751T priority patent/ATE406386T1/de
Priority to SG200506530-5A priority patent/SG161737A1/en
Priority to PCT/CU2002/000003 priority patent/WO2002081496A2/es
Priority to NZ528598A priority patent/NZ528598A/en
Priority to DE60228561T priority patent/DE60228561D1/de
Priority to PCT/CU2002/000002 priority patent/WO2002081661A2/es
Priority to KR1020037012969A priority patent/KR100946168B1/ko
Priority to NZ528599A priority patent/NZ528599A/en
Priority to PE2002000283A priority patent/PE20020972A1/es
Priority to AT02759752T priority patent/ATE378356T1/de
Priority to JP2002579482A priority patent/JP2004528033A/ja
Priority to AT06076643T priority patent/ATE477279T1/de
Priority to CA2443372A priority patent/CA2443372C/en
Priority to HR20030806A priority patent/HRP20030806B1/xx
Priority to DK02759751T priority patent/DK1384726T3/da
Priority to PL371937A priority patent/PL208109B1/pl
Priority to CA2441845A priority patent/CA2441845C/en
Priority to HK04109894.4A priority patent/HK1066818B/xx
Priority to KR1020037012938A priority patent/KR100863509B1/ko
Priority to SK1226-2003A priority patent/SK287914B6/sk
Priority to BRPI0208675-1A priority patent/BRPI0208675B1/pt
Priority to PL02371770A priority patent/PL371770A1/xx
Priority to SI200230660T priority patent/SI1411064T1/sl
Priority to US10/473,977 priority patent/US20040253233A1/en
Priority to US10/473,978 priority patent/US20050069535A1/en
Priority to EP06076643A priority patent/EP1798243B1/en
Priority to CZ20032641A priority patent/CZ296276B6/cs
Priority to HK05102752.9A priority patent/HK1070080B/xx
Priority to HR20030805A priority patent/HRP20030805B1/xx
Priority to ES02759751T priority patent/ES2312610T3/es
Priority to EP02759752A priority patent/EP1411064B1/en
Priority to MXPA03008738A priority patent/MXPA03008738A/es
Priority to HU0401695A priority patent/HU228105B1/hu
Priority to BR0208675-1A priority patent/BR0208675A/pt
Priority to SI200230766T priority patent/SI1384726T1/sl
Priority to UA2003108989A priority patent/UA75393C2/uk
Priority to UA2003108988A priority patent/UA76745C2/uk
Priority to IS6965A priority patent/IS6965A/is
Priority to IS6964A priority patent/IS2701B/is
Priority to ZA200307585A priority patent/ZA200307585B/en
Priority to EC2003004788A priority patent/ECSP034788A/es
Priority to EC2003004787A priority patent/ECSP034787A/es
Priority to ZA2003/07679A priority patent/ZA200307679B/en
Priority to IL158246A priority patent/IL158246A/en
Priority to BG108227A priority patent/BG66293B1/en
Priority to BG108228A priority patent/BG66304B1/bg
Priority to NO20034437A priority patent/NO20034437L/no
Priority to NO20034436A priority patent/NO331533B1/no
Publication of CU23007A1 publication Critical patent/CU23007A1/es
Priority to UAA200512270A priority patent/UA86768C2/ru
Priority to AU2007231687A priority patent/AU2007231687B2/en
Priority to HK07114311.6A priority patent/HK1109160B/xx
Priority to KR1020087019420A priority patent/KR100919617B1/ko
Priority to US12/407,046 priority patent/US8758753B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona con el campo deLa presente invención se relaciona con el campo de la inmunología y más específicamente con la inmun la inmunología y más específicamente con la inmunoterapia del cáncer, particularmente con combinacioterapia del cáncer, particularmente con combinaciones inmunoterapéuticas y métodos de tratamiento pones inmunoterapéuticas y métodos de tratamiento para impedir el crecimiento de células tumorales y/ara impedir el crecimiento de células tumorales y/o eliminar dichas células. Los métodos descritos eo eliminar dichas células. Los métodos descritos en la presente invención se basan en el efecto teran la presente invención se basan en el efecto terapéutico obtenido por la combinación de vacunas idipéutico obtenido por la combinación de vacunas idiotípicas cuyo principio activo es un anticuerpo anotípicas cuyo principio activo es un anticuerpo antigangliósido (Ab1) o versiones recombinantes de dtigangliósido (Ab1) o versiones recombinantes de dicho anticuerpo, con vacunas idiotípicas cuyo prinicho anticuerpo, con vacunas idiotípicas cuyo principio activo es un anticuerpo antidiotipo obtenidocipio activo es un anticuerpo antidiotipo obtenido contra un anticuerpo antigangliósido (Ab2) o vers contra un anticuerpo antigangliósido (Ab2) o versiones recombinantes del mismo, o con vacunas cuyo iones recombinantes del mismo, o con vacunas cuyo principio activo es uno o más gangliósidos. Se desprincipio activo es uno o más gangliósidos. Se describen combinaciones de estas vacunas que provocancriben combinaciones de estas vacunas que provocan un sinergismo del efecto anti-tumoral que induce un sinergismo del efecto anti-tumoral que induce cada una de las vacunas por separado, y los procedcada una de las vacunas por separado, y los procedimientos referidos pueden ser aplicados a pacienteimientos referidos pueden ser aplicados a pacientes en diferentes estadíos clínicos de tumores que ss en diferentes estadíos clínicos de tumores que sobre-expresan gangliósidos. La presente invención obre-expresan gangliósidos. La presente invención también se relaciona con la obtención de los antictambién se relaciona con la obtención de los anticuerpos recombinantes (químericos y humanizados) a uerpos recombinantes (químericos y humanizados) a partir del anticuerpo murino antigangliósido, P3 (partir del anticuerpo murino antigangliósido, P3 (Ab1) y de su anticuerpo anti-idiotipo 1E10 (Ab2). Ab1) y de su anticuerpo anti-idiotipo 1E10 (Ab2).
CU2001008420010084A 2001-04-06 2001-04-06 Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos CU23007A1 (es)

Priority Applications (81)

Application Number Priority Date Filing Date Title
CU2001008420010084A CU23007A1 (es) 2001-04-06 2001-04-06 Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
MYPI20021228A MY137078A (en) 2001-04-06 2002-04-05 Recombinant antibodies associated to gangliosides. their use indiagnosis and treatment of tumors.
ARP020101263A AR033122A1 (es) 2001-04-06 2002-04-05 Combinaciones inmunoterapeuticas para el tratamiento de tumores que sobre-expresan gangliosidos
UY27243A UY27243A1 (es) 2001-04-06 2002-04-05 Combinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos
MYPI20081190A MY145703A (en) 2001-04-06 2002-04-05 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors
ARP020101264A AR033123A1 (es) 2001-04-06 2002-04-05 Anticuerpos recombinantes asociados a gangliosidos. su uso en el diagnostico y tratamiento de tumores
MYPI20021239A MY157372A (en) 2001-04-06 2002-04-05 Immunotherapeutic combinations for the treatment of tumors that over-express gangliosides
UY27242A UY27242A1 (es) 2001-04-06 2002-04-05 Anticuerpos recombinantes asociados a gangliosidos. su uso en el diasnostico y tratamiento de tumores
EP02759751A EP1384726B1 (en) 2001-04-06 2002-04-08 Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides
AU2002308348A AU2002308348B2 (en) 2001-04-06 2002-04-08 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
CNB028086309A CN100349920C (zh) 2001-04-06 2002-04-08 神经节苷脂相关的重组抗体及其在制备肿瘤的诊断和治疗的药物中的应用
CZ2003-2668A CZ304424B6 (cs) 2001-04-06 2002-04-08 Rekombinantní protilátky související s gangliosidy a jejich použití při diagnóze a léčbě nádorů
PT02759752T PT1411064E (pt) 2001-04-06 2002-04-08 ''anticorpos recombinantes associados a gangliósidos e sua utilização no diagnóstico e tratamento de tumores''
PT02759751T PT1384726E (pt) 2001-04-06 2002-04-08 Combinações imunoterapêuticas para o tratamento de tumores que sobreexpressam gangliosidos
DK02759752T DK1411064T3 (da) 2001-04-06 2002-04-08 Gangliosid-associerede rekombinante antistoffer og anvendelsen deraf i diagnosen og behandlingen af tumorer
IL15824602A IL158246A0 (en) 2001-04-06 2002-04-08 Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides
BRPI0208676A BR0208676B1 (pt) 2001-04-06 2002-04-08 Chemical monoclonal antibody, pharmaceutical composition, and, use of a monoclonal antibody
AU2002308347A AU2002308347B2 (en) 2001-04-06 2002-04-08 Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides
EA200301097A EA006936B1 (ru) 2001-04-06 2002-04-08 Иммунотерапевтические комбинации для лечения опухолей, которые сверхэкспрессируют ганглиозиды
CNB028084330A CN1319991C (zh) 2001-04-06 2002-04-08 用于治疗过度表达神经节苷脂的肿瘤的免疫治疗组合物
SK1216-2003A SK287783B6 (sk) 2001-04-06 2002-04-08 Imunoterapeutická kombinácia na imunoterapiu nádorov, ktoré nadmerne exprimujú gangliozidy, a jej použitie
JP2002580025A JP4366080B2 (ja) 2001-04-06 2002-04-08 ガングリオシドを過剰発現する腫瘍を治療するための免疫併用療法
MXPA03008739A MXPA03008739A (es) 2001-04-06 2002-04-08 Anticuerpos recombinantes asociados a gangliosidos. su uso en el diagnostico y tratamiento de tumores.
HU0401355A HU228106B1 (en) 2001-04-06 2002-04-08 Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides
ES02759752T ES2296986T3 (es) 2001-04-06 2002-04-08 Anticuerpos recombinantes asociados a gancliosidos y el uso de los mismos en la diagnosis y el tratamiento de tumores.
EA200301098A EA006310B1 (ru) 2001-04-06 2002-04-08 Ассоциированные с ганглиозидами рекомбинантные антитела и их применение в диагностике и лечении опухолей
CN2007101021039A CN101054417B (zh) 2001-04-06 2002-04-08 神经节苷脂相关的重组抗体及其在肿瘤的诊断和治疗中的应用
DE60223547T DE60223547T2 (de) 2001-04-06 2002-04-08 Gangliosid-assoziierte rekombinante antikörper und deren verwendung bei der diagnose und behandlung von tumoren
AT02759751T ATE406386T1 (de) 2001-04-06 2002-04-08 Immunotherapeutische kombinationen zur behandlung von tumoren, die ganglioside überexprimieren
SG200506530-5A SG161737A1 (en) 2001-04-06 2002-04-08 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors
PCT/CU2002/000003 WO2002081496A2 (es) 2001-04-06 2002-04-08 Anticuerpos recombinantes asociados a gangliósidos. su uso en el diagnóstico y tratamiento de tumores
NZ528598A NZ528598A (en) 2001-04-06 2002-04-08 Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides
DE60228561T DE60228561D1 (de) 2001-04-06 2002-04-08 Immunotherapeutische kombinationen zur behandlung von tumoren, die ganglioside überexprimieren
PCT/CU2002/000002 WO2002081661A2 (es) 2001-04-06 2002-04-08 Combinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos
KR1020037012969A KR100946168B1 (ko) 2001-04-06 2002-04-08 강글리오사이드-관련 재조합 항체 및 종양의 진단 및치료에 있어서 이의 용도
NZ528599A NZ528599A (en) 2001-04-06 2002-04-08 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors
PE2002000283A PE20020972A1 (es) 2001-04-06 2002-04-08 Anticuerpos recombinantes asociados a gangliosidos
AT02759752T ATE378356T1 (de) 2001-04-06 2002-04-08 Gangliosid-assoziierte rekombinante antikörper und deren verwendung bei der diagnose und behandlung von tumoren
JP2002579482A JP2004528033A (ja) 2001-04-06 2002-04-08 ガングリオシド関連組換え抗体及び腫瘍の診断及び治療への使用
AT06076643T ATE477279T1 (de) 2001-04-06 2002-04-08 Ganglioside-assozierte rekombinante antikörper und deren gebrauch fuer diagnose und therapien von tumoren
CA2443372A CA2443372C (en) 2001-04-06 2002-04-08 Immunotherapeutic combinations for the treatment of tumors that over-express gangliosides
HR20030806A HRP20030806B1 (en) 2001-04-06 2002-04-08 Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides
DK02759751T DK1384726T3 (da) 2001-04-06 2002-04-08 Immunoterapeutiske kombinationer til behandling af tumorer, der overudtrykker gangliosider
PL371937A PL208109B1 (pl) 2001-04-06 2002-04-08 Kombinacja immunoterapeutyczna do immunoterapii nowotworów, które nadwyrażają gangliozydy i jej zastosowanie
CA2441845A CA2441845C (en) 2001-04-06 2002-04-08 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
HK04109894.4A HK1066818B (en) 2001-04-06 2002-04-08 Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides
KR1020037012938A KR100863509B1 (ko) 2001-04-06 2002-04-08 강글리오사이드를 과발현하는 종양의 치료용 면역치료 조합
SK1226-2003A SK287914B6 (sk) 2001-04-06 2002-04-08 Chimeric monoclonal antibody and its use in the preparation of medicament for the treatment of malignant tumors, cell line and pharmaceutical composition
BRPI0208675-1A BRPI0208675B1 (pt) 2001-04-06 2002-04-08 Combinação imunoterapêutica para a imunoterapia de tumores que superexpressam gangliosídeos, uso da mesma, e, uso de um método para controlar o crescimento e/ou a proliferação de tumores que superexpressam gangliosídeos
PL02371770A PL371770A1 (en) 2001-04-06 2002-04-08 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
SI200230660T SI1411064T1 (sl) 2001-04-06 2002-04-08 Rekombinantna protitelesa v povezavi z gangliozidi in njihova uporaba pri diagnozi in zdravljenju tumorjev
US10/473,977 US20040253233A1 (en) 2001-04-06 2002-04-08 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors
US10/473,978 US20050069535A1 (en) 2001-04-06 2002-04-08 Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides
EP06076643A EP1798243B1 (en) 2001-04-06 2002-04-08 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors
CZ20032641A CZ296276B6 (cs) 2001-04-06 2002-04-08 Imunoterapeutické kombinace pro lécbu nádoru, nadmerne exprimujících gangliosidy
HK05102752.9A HK1070080B (en) 2001-04-06 2002-04-08 Ganglioside-associated recombinant antibodies and the use thereof in the preparation of medicament for the diagnosis and treatment of tumors
HR20030805A HRP20030805B1 (en) 2001-04-06 2002-04-08 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
ES02759751T ES2312610T3 (es) 2001-04-06 2002-04-08 Combinaciones inmunoterapeuticas para el tratamiento de tumores que sobreexpresan gangliosidos.
EP02759752A EP1411064B1 (en) 2001-04-06 2002-04-08 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
MXPA03008738A MXPA03008738A (es) 2001-04-06 2002-04-08 Combinaciones inmunoterapeuticas para el tratamiento de tumores que sobre-expresan glangliosidos.
HU0401695A HU228105B1 (en) 2001-04-06 2002-04-08 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
BR0208675-1A BR0208675A (pt) 2001-04-06 2002-04-08 Combinação imunoterapêutica para a imunoterapaia de tumores que superexpressam gangliosìdeos, uso da mesma e método para controlar o crescimento e/ou a proliferação de células tumorais que superexpressam gangliosìdeos
SI200230766T SI1384726T1 (sl) 2001-04-06 2002-04-08 Imunoterapevtske kombinacije za zdravljenje tumorjev, ki ÄŤezmerno izraĹľajo gangliozide
UA2003108989A UA75393C2 (en) 2001-04-06 2002-08-04 Chimeric monoclonal antibody, identifying gangliosides containing n-glycolyl sialic acid, cells line producing it and pharmaceutical compositions containing it
UA2003108988A UA76745C2 (uk) 2001-04-06 2002-08-04 Імунотерапевтичні комбінації для лікування пухлин, які надекспресують гангліозиди
IS6965A IS6965A (is) 2001-04-06 2003-09-23 Ganglíósíð-tengd raðbrigða mótefni og notkun þeirra í sjúkdómsgreiningu og meðferð á æxlum
IS6964A IS2701B (is) 2001-04-06 2003-09-23 Ónæmismeðferðarsamsetningar til meðhöndlunar á æxlum sem oftjá ganglíósíð
ZA200307585A ZA200307585B (en) 2001-04-06 2003-09-29 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours.
EC2003004788A ECSP034788A (es) 2001-04-06 2003-09-30 Anticuerpos recombinantes asociados a gangliosidos su uso en el diagnostico y tratamiento de tumores
EC2003004787A ECSP034787A (es) 2001-04-06 2003-09-30 Combinaciones inmunoterapeuticas para el tratamiento de tumores que sobre expresan gangliosidos
ZA2003/07679A ZA200307679B (en) 2001-04-06 2003-10-01 Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides
IL158246A IL158246A (en) 2001-04-06 2003-10-02 Pharmaceutical compositions for the treatment of tumours that overexpress gangliosides and uses thereof
BG108227A BG66293B1 (en) 2001-04-06 2003-10-03 Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides
BG108228A BG66304B1 (bg) 2001-04-06 2003-10-03 Рекомбинантни антитела, свързващи ганглиозид и тяхното използване при диагностициране и лечение на тумори
NO20034437A NO20034437L (no) 2001-04-06 2003-10-03 Gangliosid-assosierte rekombinante antistoffer og anvendelse derav ved diagnostikk og behandling av tumorer
NO20034436A NO331533B1 (no) 2001-04-06 2003-10-03 Immunoterapeutiske kombinasjoner for behandling av tumorer som overuttrykker gangliosider
UAA200512270A UA86768C2 (ru) 2001-04-06 2005-12-20 ХИМЕРНОЕ МОНОКЛОНАЛЬНОЕ АНТИТЕЛО, ПОЛУЧЕННОЕ ИЗ МЫШИНОГО АНТИИДИОТИПИЧНОГО МОНОКЛОНАЛЬНОГО АНТИТЕЛА 1Е10, КОТОРОЕ РАСПОЗНАЕТ МЫШИНОЕ MAbР3
AU2007231687A AU2007231687B2 (en) 2001-04-06 2007-10-26 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors
HK07114311.6A HK1109160B (en) 2001-04-06 2007-12-31 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
KR1020087019420A KR100919617B1 (ko) 2001-04-06 2008-08-07 강글리오사이드-관련 재조합 항체 및 종양의 진단 및치료에 있어서 이의 용도
US12/407,046 US8758753B2 (en) 2001-04-06 2009-03-19 Ganglioside associated recombinant antibodies and the use thereof in the treatment of tumors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2001008420010084A CU23007A1 (es) 2001-04-06 2001-04-06 Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos

Publications (1)

Publication Number Publication Date
CU23007A1 true CU23007A1 (es) 2004-12-17

Family

ID=40291118

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2001008420010084A CU23007A1 (es) 2001-04-06 2001-04-06 Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos

Country Status (36)

Country Link
US (3) US20050069535A1 (es)
EP (3) EP1384726B1 (es)
JP (2) JP2004528033A (es)
KR (3) KR100863509B1 (es)
CN (3) CN100349920C (es)
AR (2) AR033123A1 (es)
AT (3) ATE406386T1 (es)
AU (3) AU2002308348B2 (es)
BG (2) BG66304B1 (es)
BR (3) BR0208675A (es)
CA (2) CA2441845C (es)
CU (1) CU23007A1 (es)
CZ (2) CZ296276B6 (es)
DE (2) DE60228561D1 (es)
DK (2) DK1384726T3 (es)
EA (2) EA006310B1 (es)
EC (2) ECSP034787A (es)
ES (2) ES2312610T3 (es)
HR (2) HRP20030805B1 (es)
HU (2) HU228106B1 (es)
IL (2) IL158246A0 (es)
IS (2) IS2701B (es)
MX (2) MXPA03008739A (es)
MY (3) MY157372A (es)
NO (2) NO20034437L (es)
NZ (2) NZ528599A (es)
PE (1) PE20020972A1 (es)
PL (2) PL371770A1 (es)
PT (2) PT1411064E (es)
SG (1) SG161737A1 (es)
SI (2) SI1384726T1 (es)
SK (2) SK287914B6 (es)
UA (3) UA75393C2 (es)
UY (2) UY27243A1 (es)
WO (2) WO2002081661A2 (es)
ZA (2) ZA200307585B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297336B2 (en) * 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
EP2329840A1 (en) * 2005-02-04 2011-06-08 Survac ApS Survivin peptide vaccine
FI20055398A0 (fi) * 2005-07-08 2005-07-08 Suomen Punainen Risti Veripalv Menetelmä solupopulaatioiden evaluoimiseksi
BRPI0614366A2 (pt) 2005-08-11 2009-10-06 Arpi Matossian Rogers peptìdeo, anticorpo ou fragmento de anticorpo, anticorpo ou ligante funcionalmente equivalente, molécula de ácido nucleico, vetor, célula hospedeira, métodos para expressar um peptìdeo, um anticorpo ou fragmento de anticorpo, um anticorpo ou ligante equivalente e para tratar uma doença em um paciente, composição farmacêutica, composição de vacina, métodos de vacinação de um indivìduo contra uma doença ou um distúrbio e de diagnose de um indivìduo para a presença de anticorpos autoimunes, e, arranjo de peptìdeos
EP2407486B1 (en) 2005-08-19 2017-11-22 Wyeth LLC Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders
ITFI20060163A1 (it) * 2006-06-29 2006-09-28 Menarini Internat Operations Luxembourg Sa Composizione farmaceutica contenente un anticorpo monoclonale anti idiotipico anti-ca-125 ed alluminio
TWI434855B (zh) * 2006-11-21 2014-04-21 Hoffmann La Roche 結合物及其在免疫分析中作為參考標準之用途
EP2255787A4 (en) * 2008-02-22 2014-08-27 Katayama Chemical Ind Co Ltd SYNTHETIC GLYCOLIPIDE-BASED LIPOSOMES
EP2166085A1 (en) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Divalent modified cells
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
NZ612647A (en) * 2009-03-10 2015-03-27 Biogen Idec Inc Anti-bcma antibodies
MX2011010264A (es) * 2009-04-01 2011-10-11 Genentech Inc Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso.
CU23736A1 (es) * 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
CA2780713A1 (en) * 2009-09-03 2011-03-10 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
US9469685B2 (en) * 2011-01-10 2016-10-18 Emory University Antibodies directed against influenza
CU24070B1 (es) 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
EP2641916A1 (en) * 2012-03-23 2013-09-25 Centre National de la Recherche Scientifique (C.N.R.S) Novel antibodies anti-sPLA2-IIA and uses thereof
WO2013186719A1 (en) 2012-06-15 2013-12-19 Pfizer Inc. Improved antagonist antibodies against gdf-8 and uses therefor
AR096687A1 (es) 2013-06-24 2016-01-27 Genentech Inc Anticuerpos anti-fcrh5
CA3131724A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Anti-cd3 antibodies and methods of use
EP3662928A1 (en) * 2014-04-10 2020-06-10 OBI Pharma Inc. Antibodies binding to tumour associated carbohydrate antigens, pharmaceutical compositions and uses thereof
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
KR20250021639A (ko) 2015-06-16 2025-02-13 제넨테크, 인크. FcRH5에 대한 인간화 및 친화도 성숙 항체 및 사용방법
WO2018017864A2 (en) * 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
WO2018102536A1 (en) 2016-11-30 2018-06-07 Oncomed Pharmaceuticals, Inc. Methods for treatment of cancer comprising tigit-binding agents
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2754206B2 (ja) * 1987-11-17 1998-05-20 メクト株式会社 α２→３結合を認識するモノクローナル抗体
US6051225A (en) * 1988-10-19 2000-04-18 The Dow Chemical Company Family of high affinity, modified antibodies for cancer treatment
EP0586002B1 (en) * 1992-08-18 2000-01-19 CENTRO de IMMUNOLOGIA MOLECULAR Monoclonal antibodies recognizing the epidermal growth factor receptor, cells and methods for their production and compositions containing them
JPH07101999A (ja) * 1993-10-06 1995-04-18 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列
EP0657471B1 (en) * 1993-12-09 2001-10-24 Centro de Inmunologia Molecular Anti ganglioside monoclonal antibodies and their use in the specific active immunotherapy of malignant tumours
CU22702A1 (es) * 1997-10-21 2001-07-31 Centro Inmunologia Molecular Anticuerpos monoclonales anti - idiotipo, su uso en la inmunoterapia activa de tumores malignos, hibridoma que los produce y composiciones que los contienen
US6063379A (en) * 1993-12-09 2000-05-16 Centro De Inmunologia Molecular Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CU22731A1 (es) * 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies

Also Published As

Publication number Publication date
US8758753B2 (en) 2014-06-24
NZ528599A (en) 2005-03-24
ATE477279T1 (de) 2010-08-15
NO20034436L (no) 2003-12-02
PT1411064E (pt) 2008-02-12
PT1384726E (pt) 2008-12-05
WO2002081496A2 (es) 2002-10-17
CN1319991C (zh) 2007-06-06
HUP0401355A3 (en) 2012-05-29
MY157372A (en) 2016-06-15
AU2007231687A1 (en) 2007-11-22
BG108227A (bg) 2005-04-30
HRP20030805A2 (en) 2005-08-31
CN101054417B (zh) 2012-07-11
HU228105B1 (en) 2012-11-28
BRPI0208675B1 (pt) 2018-03-13
EP1798243A2 (en) 2007-06-20
DE60223547D1 (de) 2007-12-27
EA006310B1 (ru) 2005-10-27
NO20034437D0 (no) 2003-10-03
JP4366080B2 (ja) 2009-11-18
ATE378356T1 (de) 2007-11-15
CA2443372A1 (en) 2002-10-17
PL371770A1 (en) 2005-06-27
CZ304424B6 (cs) 2014-04-30
EP1411064B1 (en) 2007-11-14
BR0208676A (pt) 2008-04-08
EA006936B1 (ru) 2006-06-30
IL158246A (en) 2010-05-31
UA75393C2 (en) 2006-04-17
CA2441845A1 (en) 2002-10-17
DK1411064T3 (da) 2008-03-25
BG66293B1 (en) 2013-02-28
SK12262003A3 (sk) 2004-08-03
UA76745C2 (uk) 2006-09-15
HUP0401695A2 (en) 2006-08-28
EP1798243B1 (en) 2010-08-11
AU2002308348B2 (en) 2007-11-22
EP1384726A2 (en) 2004-01-28
EP1798243A3 (en) 2007-10-17
JP2004528033A (ja) 2004-09-16
NO331533B1 (no) 2012-01-23
AU2002308347B2 (en) 2006-09-14
NO20034436D0 (no) 2003-10-03
PL208109B1 (pl) 2011-03-31
ZA200307585B (en) 2004-09-16
KR100946168B1 (ko) 2010-03-11
KR20030087053A (ko) 2003-11-12
WO2002081661A2 (es) 2002-10-17
UY27242A1 (es) 2002-07-31
ZA200307679B (en) 2005-03-30
UY27243A1 (es) 2002-09-30
ECSP034787A (es) 2004-01-28
MY137078A (en) 2008-12-31
PE20020972A1 (es) 2003-01-02
SI1384726T1 (sl) 2009-04-30
DE60223547T2 (de) 2008-09-18
HRP20030806A2 (en) 2005-08-31
CZ20032641A3 (cs) 2004-07-14
BG66304B1 (bg) 2013-03-29
KR20030092048A (ko) 2003-12-03
CA2441845C (en) 2011-06-07
CZ20032668A3 (cs) 2004-07-14
SK12162003A3 (sk) 2004-05-04
KR20080080680A (ko) 2008-09-04
NO20034437L (no) 2003-12-02
IS6965A (is) 2003-09-23
HU228106B1 (en) 2012-11-28
BR0208675A (pt) 2004-08-03
HUP0401695A3 (en) 2012-05-29
BR0208676B1 (pt) 2017-11-14
HK1070080A1 (zh) 2005-06-10
IL158246A0 (en) 2004-05-12
JP2004525953A (ja) 2004-08-26
SG161737A1 (en) 2010-06-29
HK1066818A1 (en) 2005-04-01
MXPA03008738A (es) 2003-12-11
CZ296276B6 (cs) 2006-02-15
MY145703A (en) 2012-03-30
BG108228A (bg) 2005-04-30
AR033122A1 (es) 2003-12-03
CN1507452A (zh) 2004-06-23
SI1411064T1 (sl) 2008-04-30
US20040253233A1 (en) 2004-12-16
HK1109160A1 (en) 2008-05-30
SK287783B6 (sk) 2011-09-05
IS2701B (is) 2010-11-15
ECSP034788A (es) 2004-01-28
AU2007231687B2 (en) 2010-09-30
HRP20030805B1 (en) 2011-11-30
KR100863509B1 (ko) 2008-10-15
MXPA03008739A (es) 2003-12-11
EA200301098A1 (ru) 2004-04-29
UA86768C2 (ru) 2009-05-25
CN100349920C (zh) 2007-11-21
HUP0401355A2 (hu) 2004-10-28
US20100297008A1 (en) 2010-11-25
US20050069535A1 (en) 2005-03-31
ES2312610T3 (es) 2009-03-01
CN1535282A (zh) 2004-10-06
ATE406386T1 (de) 2008-09-15
ES2296986T3 (es) 2008-05-01
HRP20030806B1 (en) 2011-11-30
EP1384726B1 (en) 2008-08-27
DE60228561D1 (de) 2008-10-09
WO2002081661A3 (es) 2003-01-03
WO2002081496A3 (es) 2004-02-19
PL371937A1 (en) 2005-07-11
SK287914B6 (sk) 2012-03-02
IS6964A (is) 2003-09-23
EP1411064A2 (en) 2004-04-21
EA200301097A1 (ru) 2004-02-26
CA2443372C (en) 2013-05-28
CN101054417A (zh) 2007-10-17
DK1384726T3 (da) 2008-12-15
NZ528598A (en) 2005-03-24
AR033123A1 (es) 2003-12-03
KR100919617B1 (ko) 2009-09-29

Similar Documents

Publication Publication Date Title
CU23007A1 (es) Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
TNSN05300A1 (en) Treatment with anti-vegf antibodies
CY1112473T1 (el) Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα
NZ527283A (en) Modified antibodies and methods of use
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
CL2022003715A1 (es) Tubulisinas y conjugados de proteinas-tubulisina
MX2023001776A (es) Anticuerpos contra ilt2 y uso de los mismos.
CU22979A1 (es) Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
Facciabene et al. 572 Gut microbiota tuning promotes tumor-associated antigen cross-presentation and enhances CAR T antitumor effects
CY1108612T1 (el) Ανοσοθεραπευτικοι συνδυασμοι για την αγωγη ογκων που υπερεκφραζουν γαγγλιοσιδες
US20050163707A1 (en) Cancer treatment
NO924803L (no) Tumor-relatert monoklonalt antistoff 88bv59
Stephenson Reengineered monoclonal antibodies step up to the plate in cancer studies
Volkova et al. Updates in urologic oncology guidelines: prostate cancer: A review
FI935038A0 (fi) Tumoer associerad monoklonal antikropp 81AV78
RU2003117815A (ru) Способ лечения неоперабельного рака легкого
LV15336A (lv) Metode vēža metastāžu noteikšanai un vēža šūnu bloķēšanai in vitro
Witkowska et al. The role of antibody-based therapies in treating relapsed chronic lymphocytic leukemia